John R. Moore - 08 Jun 2022 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
General Counsel
Signature
/s/ John R. Moore
Issuer symbol
EWTX
Transactions as of
08 Jun 2022
Net transactions value
-$156,491
Form type
4
Filing time
10 Jun 2022, 18:34:07 UTC
Previous filing
07 Jun 2022
Next filing
15 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $8,922 +12,566 +419% $0.7100* 15,566 08 Jun 2022 Direct F1
transaction EWTX Common Stock Sale $83,362 -12,566 -81% $6.63 3,000 08 Jun 2022 Direct F2
transaction EWTX Common Stock Options Exercise $5,407 +7,615 +254% $0.7100* 10,615 09 Jun 2022 Direct
transaction EWTX Common Stock Sale $49,397 -7,615 -72% $6.49 3,000 09 Jun 2022 Direct F3
transaction EWTX Common Stock Options Exercise $5,059 +7,125 +238% $0.7100* 10,125 10 Jun 2022 Direct
transaction EWTX Common Stock Sale $43,120 -7,125 -70% $6.05 3,000 10 Jun 2022 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -12,566 -6.7% $0.000000 175,606 08 Jun 2022 Common Stock 12,566 $0.7100 Direct F5
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -7,615 -4.3% $0.000000 167,991 09 Jun 2022 Common Stock 7,615 $0.7100 Direct F5
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -7,125 -4.2% $0.000000 160,866 10 Jun 2022 Common Stock 7,125 $0.7100 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022.
F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.44 to $6.73, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.39 to $6.65, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.43, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.